APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability

AIDS Research and Human Retroviruses

Volumn 28, Issue 6, 2012, Pages 619-627

  De Maio, Federico A ^a   Rocco, Carlos A ^a   Aulicino, Paula C ^a   Bologna, Rosa ^a   Mangano, Andrea ^a   Sen, Luisa ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; POL PROTEIN; PURINE; VIF PROTEIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PERINATAL INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ARGENTINA; CHILD; CULLIN PROTEINS; CYTIDINE DEAMINASE; FEMALE; GENETIC VARIATION; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84861892563     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0291     Document Type: Article

References (46)

1. Albin JS and Harris RS: Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: Implications for therapeutics. Expert Rev Mol Med 2010;12:e4.
2. Henriet S, Mercenne G, Bernacchi S, Paillart JC, and Marquet R: Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 2009;73:211-232.
3. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, and Mallal S: Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 2006;80:9259-9269.
4. Vázquez-Pérez JA, Ormsby CE, Hernández-Juan R, Torres KJ, and Reyes-Terán G: APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 2009;6:23.
5. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, Wachihi C, Kimani J, and Plummer FA: Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 2008;82:8172-8182.
6. Mulder LC, Harari A, and Simon V: Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci USA 2008;105:5501-5506.
7. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, and Seoighe C: HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 2009;5:e1000414.
8. Fourati S, Malet I, Binka M, Boukobza S, Wirden M, Sayon S, Simon A, Katlama C, Simon V, Calvez V, and Marcelin AG: Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS 2010;24:2313-2321.
9. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, Malim MH, and Wolinsky SM: Human APOBEC3Gmediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 2010;84:10402-10405.
10. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, Trono D, Vlahov D, Donfield S, Goedert JJ, Phair J, Buchbinder S, ÓBrien SJ, Telenti A, and Winkler CA: APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004;78:11070-11076.
11. Do H, Vasilescu A, Diop G, Hirtzig T, Heath SC, Coulonges C, Rappaport J, Therwath A, Lathrop M, Matsuda F, and Zagury JF: Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis 2005;191:159-163.
12. Valcke HS, Bernard NF, Bruneau J, Alary M, Tsoukas CM, and Roger M: APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 2006;20:1984-1986.
13. An P, Duggal P, Wang LH, ÓBrien SJ, Donfield S, Goedert JJ, Phair J, Buchbinder S, Kirk GD, and Winkler CA: Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet 2007;3:e19.
14. Reddy K, Winkler CA, Werner L, Mlisana K, Abdool Karim SS, Ndunǵu T, and the CAPRISA Acute Infection Study Team: APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4 + T-cell counts and plasma viral load. AIDS 2010;24:195-204.
15. De Maio FA, Rocco CA, Aulicino PC, Bologna R, Mangano A, and Sen L: Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms. Infect Genet Evol 2011;11:1256-1262.
16. Feng Y and Chelico L: Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J Biol Chem 2011;286:11415-11426.
17. Hassaine G, Agostini I, Candotti D, Bessou G, Caballero M, Agut H, Autran B, Barthalay Y, and Vigne R: Characterization of human immunodeficiency virus type 1 vif gene in longterm asymptomatic individuals. Virology 2000;276: 169-180.
18. Alexander L, Aquino-DeJesus MJ, Chan M, and Andiman WA: Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol 2002;76:10533-10539.
19. Farrow MA, Somasundaran M, Zhang C, Gabuzda D, Sullivan JL, and Greenough TC: Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation. AIDS Res Hum Retroviruses 2005;21:565-574.
20. Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, and Kanki PJ: The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1- infected individuals. AIDS Res Hum Retroviruses 2008;24: 1285-1290.
21. Sandonís V, Casado C, Alvaro T, Pernas M, Olivares I, García S, Rodríguez C, del Romero J, and Ló pez-Galíndez C: A combination of defective DNA and protective host factors are found in a set of HIV-1 ancestral LTNPs. Virology 2009;391:73-82.
22. Rangel HR, Garzaro D, Rodríguez AK, Ramírez AH, Ameli G, Del Rosario Gutiérrez C, and Pujol FH: Deletion, insertion and stop codon mutations in vif genes of HIV-1 infecting slow progressor patients. J Infect Dev Ctries 2009;3:531-538.
23. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, and Blankson JN: Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 2008;82:3125-3130.
24. Piantadosi A, Humes D, Chohan B, McClelland RS, and Overbaugh J: Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol 2009;83:7805-7814.
25. Gourraud PA, Karaouni A, Woo JM, Schmidt T, Oksenberg JR, Hecht FM, Liegler TJ, and Barbour JD: APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Hum Immunol 2011;72:207-212.
26. Koulinska IN, Chaplin B, Mwakagile D, Essex M, and Renjifo B: Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS Res Hum Retroviruses 2003;19:1115-1123.
27. Amoedo ND, Afonso AO, Cunha SM, Oliveira RH, Machado ES, et al.: Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PLoS ONE 2011;6: e24118.
28. Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, and Rogers MF: 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43:1-10.
29. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, ÓSullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-1180.
30. Janini M, Rogers M, Birx DR, and McCutchan FE: Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4( + ) T cells. J Virol 2001;75:7973-7986.
31. Suspène R, Henry M, Guillot S, Wain-Hobson S, and Vartanian JP: Recovery of APOBEC3-edited human immunodeficiency virus G- >A hypermutants by differential DNA denaturation PCR. J Gen Virol 2005;86:125-129.
32. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, and Kumar S: MEGA5: Molecular Evolutionary Genetics Analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011;28:2731-2739.
33. Suspène R, Rusniok C, Vartanian JP, and Wain-Hobson S: Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 2006;34:4677-4684.
34. Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, Hance AJ, and Clavel F: Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J Virol 2006;80:3679-3683.
35. Armitage AE, Katzourakis A, De Oliveira T, Welch JJ, Belshaw R, Bishop KN, Kramer B, McMichael AJ, Rambaut A, and Iversen AK: Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K (HML2) sequences. J Virol 2008;82:8743-8761.
36. Hu C, Saenz DT, Fadel HJ, Walker W, Peretz M, and Poeschla EM: The HIV-1 Central polypurine tract function as a second line of defense against APOBEC3G/F. J Virol 2010;84:11981-11993.
37. Sadler HA, Stenglein MD, Harris RS, Mansky LM: APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 2010;84:7396-7404.
38. Simon V, Zennou V, Murray D, Huang Y, Ho DD, and Bieniasz PD: Natural variation in Vif: Differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 2005;1:e6.
39. Russell RA and Pathak VK: Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007;81:8201-8210.
40. Mehle A, Thomas ER, Rajendran KS, and Gabuzda D: A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 2006;281:17259-17265.
41. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, and Yu XF: Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006;349:290-299.
42. Donahue JP, Vetter ML, Mukhtar NA, and D́Aquila RT: The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 2008;377:49-53.
43. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, Yu XF, and Xiong Y: Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 2008;82:8656-8663.
44. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, Malim MH, and Sanderson MR: The SOCSbox of HIV-1 Vif interacts with ElonginBC by inducedfolding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog 2010;6:e1000925.
45. Yang S, Sun Y, and Zhang H: The multimerization of human immunodeficiency virus type I Vif protein: A requirement for Vif function in the viral life cycle. J Biol Chem 2001;276:4889-4893.
46. Henzler T, Harmache A, Herrmann H, Spring H, Suzan M, Audoly G, Panek T, and Bosch V: Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure. J Gen Virol 2001;82:561-573.